EverGlade Consulting announced that it supported Landmark Bio in securing up to $18.3 million in funding from Advanced Research Projects Agency for Health. The award will fund the development of a scalable continuous manufacturing platform for extracellular vesicles, a technology with potential applications across advanced therapies, including viral vectors and cell therapies.
The funding is part of ARPA-H’s TRANSFORM-EV program, which aims to enable access to transformative therapies by enabling continuous manufacturing of extracellular vesicles. Over the course of the three-year project, Landmark Bio will work to integrate advanced upstream, downstream, and analytical manufacturing technologies to replace low-yield, high-cost batch production methods. The goal is to expand global access to EV-based therapeutics and similar next-generation treatments.
EverGlade played a central role in guiding Landmark Bio through the federal funding process, including negotiations, project structuring, and financial planning. The firm specializes in helping innovators navigate complex government funding ecosystems, supporting engagements with agencies such as ARPA-H, BARDA, and DARPA.
Landmark Bio, an Artis BioSolutions company, operates from its facility in Watertown, Massachusetts, where it provides integrated capabilities spanning process development, advanced analytics, and GMP manufacturing. The company focuses on helping biotechnology and pharmaceutical partners scale advanced therapies from development through commercialization.
KEY QUOTES:
“EverGlade was a huge help as we worked through negotiations with the government. The team supported several redesigns across our statement of work, milestones, and financials, including cost volumes and bases of estimate and we look forward to leveraging EverGlade’s project management and financial expertise in the post-award phase.”
Gregg Nyberg, Chief Technology Officer, Landmark Bio
“We couldn’t be more excited for Landmark Bio and for the scientific community as a whole for this award. This program represents a meaningful step forward in advancing scalable manufacturing for next-generation therapeutics, and we’re proud to support the Landmark Bio team as they move into the execution phase.”
Giacomo Apadula, CEO, EverGlade Consulting
